Literature DB >> 16704928

Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion.

Craig E Daniels1, Jeffrey L Myers, James P Utz, Svetomir N Markovic, Jay H Ryu.   

Abstract

BACKGROUND: Organizing pneumonia (OP) is a distinct histopathologic lesion that occurs in a variety of clinical contexts. There have been occasional reports of OP occurring in patients with hematologic malignancies. STUDY
OBJECTIVES: To examine the association of OP with hematologic malignancies and to assess the clinical course of affected patients.
DESIGN: A retrospective review of our institutional experience of unexplained OP developing in patients with hematologic malignancies.
SETTING: Tertiary care, referral medical center. PATIENTS: We identified 6 patients with a verified histopathologic diagnosis of OP and antecedent or concomitant diagnosis of a hematologic malignancy from the Mayo Clinic database (1995-2003). Clinical, radiologic, and outcome data were abstracted from records.
RESULTS: Underlying hematologic disorders included lymphoma (2), acute leukemia (2), cutaneous T-cell lymphoma (1), and myelodysplastic syndrome (1). OP was diagnosed by surgical lung biopsy in 4 and bronchoscopic biopsy in 2. Four of the 6 patients had previously been exposed to chemotherapeutic agents, two had not. Three of the 6 patients had bone marrow transplantation prior to development of OP. Five patients were treated with prednisone and all experienced symptomatic improvement with documented radiologic resolution in 4. One patient experienced symptomatic and radiologic resolution with observation alone. Three patients ultimately died from complications of their underlying hematologic disorder and 1 patient died of unknown causes. Two patients were alive without respiratory complaints more than 1 year after lung biopsy.
CONCLUSIONS: OP occurs in patients with underlying hematologic malignancies who may or may not have been treated with chemotherapy and responds favorably to corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16704928     DOI: 10.1016/j.rmed.2006.03.035

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Interstitial pneumonia associated with progression of myelodysplastic syndrome.

Authors:  Keisuke Kataoka; Motoshi Ichikawa; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2009-05-20       Impact factor: 2.490

2.  An unusual pulmonary complication of cytomegalovirus infection in a renal transplant recipient.

Authors:  Jeremy Jacques; Aymeric Dallocchio; Zara Dickson; Frederique Bocquentin; Hela Jebali; Jean-Claude Aldigier; Marie Essig; Jean-Philippe Rerolle
Journal:  NDT Plus       Date:  2008-05-21

3.  Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation.

Authors:  Takeru Asano; Nobuharu Fujii; Daigo Niiya; Hisakazu Nishimori; Keiko Fujii; Ken-Ichi Matsuoka; Koichi Ichimura; Toshihisa Hamada; Eisei Kondo; Yoshinobu Maeda; Yasushi Tanimoto; Katsuji Shinagawa; Mitsune Tanimoto
Journal:  Springerplus       Date:  2014-01-02

Review 4.  [Cryptogenic organizing pneumonia versus secondary organizing pneumonia].

Authors:  Rosemarie Krupar; Christiane Kümpers; Alexander Haenel; Sven Perner; Florian Stellmacher
Journal:  Pathologe       Date:  2021-01-18       Impact factor: 1.011

5.  Characteristics and Follow-Up of Organizing Pneumonia Associated with Haematological Malignancies.

Authors:  Huihui Zeng; Yiming Ma; Xue He; Shan Cai; Ping Chen; Yan Chen; Hong Luo
Journal:  Int J Gen Med       Date:  2022-01-07

6.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  G Maschmeyer; J Carratalà; D Buchheidt; A Hamprecht; C P Heussel; C Kahl; J Lorenz; S Neumann; C Rieger; M Ruhnke; H Salwender; M Schmidt-Hieber; E Azoulay
Journal:  Ann Oncol       Date:  2014-05-15       Impact factor: 32.976

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.